Literature DB >> 9879352

[The value of gallium scintigraphy after the therapy of Hodgkin's disease].

S Staar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9879352     DOI： 10.1007/bf03038513

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  6 in total

1.  Present state and future role of gallium-67 scintigraphy in lymphoma.

Authors:  D Front; O Israel
Journal:  J Nucl Med       Date:  1996-03       Impact factor: 10.057

2.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

Authors:  F Moog; M Bangerter; C G Diederichs; A Guhlmann; J Kotzerke; E Merkle; O Kolokythas; F Herrmann; S N Reske
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

3.  The value of gallium imaging after therapy for Hodgkin's disease.

Authors:  J A Bogart; C T Chung; N F Mariados; A I Vermont; S M Lemke; S Grethlein; S L Graziano
Journal:  Cancer       Date:  1998-02-15       Impact factor: 6.860

4.  Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.

Authors:  M Hill; D Cunningham; D MacVicar; A Roldan; J Husband; R McCready; J Mansi; S Milan; T Hickish
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

Review 5.  New diagnostic imaging procedures in Hodgkin's disease.

Authors:  M Bangerter; M Griesshammer; T Binder; M Hafner; H Heimpel; S N Reske; N Frickhofen
Journal:  Ann Oncol       Date:  1996       Impact factor: 32.976

6.  Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.

Authors:  O S Hoekstra; G J Ossenkoppele; R Golding; A van Lingen; G W Visser; G J Teule; P C Huijgens
Journal:  J Nucl Med       Date:  1993-10       Impact factor: 10.057
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.